创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

张林丽, 贾安, 张瑱. 心血管药理研究进展[J]. 药学进展, 2019, 43(8): 603-613.
引用本文: 张林丽, 贾安, 张瑱. 心血管药理研究进展[J]. 药学进展, 2019, 43(8): 603-613.
ZHANG Linli, JIA An, ZHANG Zhen. Research Progress in Cardiovascular Pharmacology[J]. Progress in Pharmaceutical Sciences, 2019, 43(8): 603-613.
Citation: ZHANG Linli, JIA An, ZHANG Zhen. Research Progress in Cardiovascular Pharmacology[J]. Progress in Pharmaceutical Sciences, 2019, 43(8): 603-613.

心血管药理研究进展

Research Progress in Cardiovascular Pharmacology

  • 摘要: 近年来,我国心血管药理工作者在冠心病、心肌梗死、缺血再灌注损伤、动脉粥样硬化等心血管疾病方面进行了系统深入的研究,探讨了与心血管疾病相关的发病机制和干预靶点、药物的药理作用机制和治疗药物等。通过检索我国学者2016—2017年在国外学术期刊上发表的文献,综述我国学者在心血管药理领域所取得的研究进展,以期为后续相关药物研究提供参考。

     

    Abstract: In recent years, Chinese cardiovascular pharmacologists have made systematically in-depth study on cardiovascular diseases such as coronary heart disease, myocardial infarction, ischemia reperfusion injury, and atherosclerosis, investigating their pathogeneses and targets for intervention, as well as therapeutic drugs and the pharmacological mechanisms of action. By retrieving papers published in high-level academic journals during 2016-2017 by Chinese scholars, this paper reviewed research progress made by Chinese scholar in the field of cardiovascular pharmacology, providing reference for further research of relevant drugs.

     

/

返回文章
返回